# Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches

DOI: 10.1080/17476348.2016.1177460
Expert Review of Respiratory Medicine, 2016, 10, 685-97.

| # | Paper | IF | Citations |
|---|---|---|---|
| 91 | Electrochemical sensors for identifying pyocyanin production in clinical Pseudomonas aeruginosa isolates. *Biosensors and Bioelectronics*, **2017**, 97, 65-69 | 11.8 | 43 |
| 90 | New horizons for cystic fibrosis treatment. *Pharmacology & Therapeutics*, **2017**, 170, 205-211 | 13.9 | 36 |
| 89 | Relevance of multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis. *International Journal of Medical Microbiology*, **2017**, 307, 353-362 | 3.7 | 54 |
| 88 | Multilocus amplicon sequencing of Pseudomonas aeruginosa cystic fibrosis airways isolates collected prior to and after early antipseudomonal chemotherapy. *Journal of Cystic Fibrosis*, **2017**, 16, 346-352 | 4.1 | 3 |
| 87 | Biofilm Structures in a Mono-Associated Mouse Model of Infection. *Frontiers in Microbiology*, **2017**, 8, 2086 | 5.7 | 30 |
| 86 | Ethanolic Allium sativum extract down-regulates the pelF gene involved in Pseudomonas aeruginosa biofilm formation. *African Journal of Biotechnology*, **2017**, 16, 585-593 | 0.6 | |
| 85 | Long-Term Microevolution of Pseudomonas aeruginosa Differs between Mildly and Severely Affected Cystic Fibrosis Lungs. *American Journal of Respiratory Cell and Molecular Biology*, **2018**, 59, 246-256 | 5.7 | 26 |
| 84 | Pore-forming activity of the Pseudomonas aeruginosa type III secretion system translocon alters the host epigenome. *Nature Microbiology*, **2018**, 3, 378-386 | 26.6 | 31 |
| 83 | Lifestyle transitions and adaptive pathogenesis of Pseudomonas aeruginosa. *Current Opinion in Microbiology*, **2018**, 41, 15-20 | 7.9 | 78 |
| 82 | Occurrence of Pseudomonas aeruginosa in waters: implications for patients with cystic fibrosis (CF). *Letters in Applied Microbiology*, **2018**, 66, 537-541 | 2.9 | 19 |
| 81 | Small Noncoding Regulatory RNAs from and Complex. *International Journal of Molecular Sciences*, **2018**, 19, | 6.3 | 13 |
| 80 | Activity of a novel antimicrobial peptide against Pseudomonas aeruginosa biofilms. *Scientific Reports*, **2018**, 8, 14728 | 4.9 | 29 |
| 79 | Higher Prevalence of PldA, a -Kingdom H2-Type VI Secretion System Effector, in Clinical Isolates Responsible for Acute Infections and in Multidrug Resistant Strains. *Frontiers in Microbiology*, **2018**, 9, 2578 | 5.7 | 10 |
| 78 | Chronic Infections: A Possible Scenario for Autophagy and Senescence Cross-Talk. *Cells*, **2018**, 7, | 7.9 | 9 |
| 77 | How to manage infections. *Drugs in Context*, **2018**, 7, 212527 | 5.2 | 291 |
| 76 | Identification of FDA-Approved Drugs as Antivirulence Agents Targeting the Quorum-Sensing System of Pseudomonas aeruginosa. *Antimicrobial Agents and Chemotherapy*, **2018**, 62, | 5.9 | 51 |
| 75 | Metabolic Phenotyping and Strain Characterisation of Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients Using Rapid Evaporative Ionisation Mass Spectrometry. *Scientific Reports*, **2018**, 8, 10952 | 4.9 | 13 |

| | | | |
|---|---|---|---|
| 74 | Antimicrobial Treatment of in Patients With Cystic Fibrosis. *Frontiers in Pharmacology*, **2019**, 10, 849 | 5.6 | 12 |
| 73 | Synthesis and characterization of chitosan oligosaccharide-capped gold nanoparticles as an effective antibiofilm drug against the Pseudomonas aeruginosa PAO1. *Microbial Pathogenesis*, **2019** , 135, 103623 | 3.8 | 36 |
| 72 | A 2.5-years within-patient evolution of a with acquisition of ceftolozane-tazobactam and ceftazidime-avibactam resistance upon treatment. *Antimicrobial Agents and Chemotherapy*, **2019**, | 5.9 | 13 |
| 71 | Intermittent colonisation with Methicillin-Resistant can be eradicated from the Airways of Adults with Cystic Fibrosis. *Antibiotics*, **2019**, 8, | 4.9 | 1 |
| 70 | Small Is Mighty-Chemical Communication Systems in. *Annual Review of Microbiology*, **2019**, 73, 559-578 | 17.5 | 24 |
| 69 | A 2-Year Single-Centre Audit on Antibiotic Resistance of , and Strains from an Intensive Care Unit and Other Wards in a General Public Hospital in Greece. *Antibiotics*, **2019**, 8, | 4.9 | 16 |
| 68 | Development of an effective fluorescence probe for discovery of aminopeptidase inhibitors to suppress biofilm formation. *Journal of Antibiotics*, **2019**, 72, 461-468 | 3.7 | 1 |
| 67 | Bacterial killing is enhanced by exogenous administration of lysozyme in the lungs. *Respiratory Medicine and Research*, **2019**, 76, 22-27 | 1.4 | 5 |
| 66 | Vancomycin-induced gut dysbiosis during Pseudomonas aeruginosa pulmonary infection in a mice model. *Journal of Leukocyte Biology*, **2020**, 107, 95-104 | 6.5 | 7 |
| 65 | Cephalosporin nitric oxide-donor prodrug DEA-C3D disperses biofilms formed by clinical cystic fibrosis isolates of Pseudomonas aeruginosa. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 117-125 | 5.1 | 20 |
| 64 | Expression of the MexXY Aminoglycoside Efflux Pump and Presence of an Aminoglycoside-Modifying Enzyme in Clinical Pseudomonas aeruginosa Isolates Are Highly Correlated. *Antimicrobial Agents and Chemotherapy*, **2020**, 65, | 5.9 | 5 |
| 63 | Untargeted LC-MS Metabolomics Differentiates Between Virulent and Avirulent Clinical Strains of. *Biomolecules*, **2020**, 10, | 5.9 | 9 |
| 62 | Bronchial Infection due to Pseudomonas Aeruginosa in Patients with Cystic Fibrosis Diagnosed in Neonatal Screening. *Archivos De Bronconeumologia*, **2020**, 56, 532-534 | 0.7 | 0 |
| 61 | Airway Mucins Inhibit Oxidative and Non-Oxidative Bacterial Killing by Human Neutrophils. *Frontiers in Pharmacology*, **2020**, 11, 554353 | 5.6 | 2 |
| 60 | Spray-dried multidrug particles for pulmonary co-delivery of antibiotics with N-acetylcysteine and curcumin-loaded PLGA-nanoparticles. *European Journal of Pharmaceutics and Biopharmaceutics*, **2020**, 157, 200-210 | 5.7 | 8 |
| 59 | Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance. *Clinical Infectious Diseases*, **2021**, 73, e4599-e4606 | 11.6 | 13 |
| 58 | Clinical Biofilm Ring Test Reveals the Potential Role of β-Lactams in the Induction of Biofilm Formation by in Cystic Fibrosis Patients. *Pathogens*, **2020**, 9, | 4.5 | 2 |
| 57 | Comparative evaluation of the effect of different growth media on in vitro sensitivity to azithromycin in multi-drug resistant Pseudomonas aeruginosa isolated from cystic fibrosis patients. *Antimicrobial Resistance and Infection Control*, **2020**, 9, 197 | 6.2 | 2 |

| | | | |
|---|---|---|---|
| 56 | Antimicrobial Resistance in ESKAPE Pathogens. *Clinical Microbiology Reviews*, **2020**, 33, | 34 | 290 |
| 55 | Building a better biofilm - Formation of -like biofilm structures by in a porcine model of cystic fibrosis lung infection. *Biofilm*, **2020**, 2, 100024 | 5.9 | 15 |
| 54 | Detection of alanyl aminopeptidase as a biomarker for in the sputum of patients with cystic fibrosis using exogenous volatile organic compound evolution.. *RSC Advances*, **2020**, 10, 10634-10645 | 3.7 | 2 |
| 53 | Anti-Infectives Restore ORKAMBI Rescue of F508del-CFTR Function in Human Bronchial Epithelial Cells Infected with Clinical Strains of. *Biomolecules*, **2020**, 10, | 5.9 | 21 |
| 52 | Intraclonal competitive fitness of longitudinal cystic fibrosis Pseudomonas aeruginosa airway isolates in liquid cultures. *Environmental Microbiology*, **2020**, 22, 2536-2549 | 5.2 | 2 |
| 51 | Clinical characteristics and outcomes associated with Inquilinus infection in cystic fibrosis. *Journal of Cystic Fibrosis*, **2021**, 20, 310-315 | 4.1 | 2 |
| 50 | Serum -Glycomics Stratifies Bacteremic Patients Infected with Different Pathogens. *Journal of Clinical Medicine*, **2021**, 10, | 5.1 | 4 |
| 49 | Phenotypic and Genotypic Adaptations in Pseudomonas aeruginosa Biofilms following Long-Term Exposure to an Alginate Oligomer Therapy. *MSphere*, **2021**, 6, | 5 | 3 |
| 48 | A Panel of Diverse Pseudomonas aeruginosa Clinical Isolates for Research and Development. | | |
| 47 | Bacterial Membrane Vesicles in Pneumonia: From Mediators of Virulence to Innovative Vaccine Candidates. *International Journal of Molecular Sciences*, **2021**, 22, | 6.3 | 8 |
| 46 | Type 3 secretion system of Pseudomonas aeruginosa. *Microbiological Research*, **2021**, 246, 126719 | 5.3 | 13 |
| 45 | Clinical characteristics of Pseudomonas and Aspergillus co-infected cystic fibrosis patients: A UK registry study. *Journal of Cystic Fibrosis*, **2021**, | 4.1 | 3 |
| 44 | Comparative genome analysis of multidrug-resistant Pseudomonas aeruginosa JNQH-PA57, a clinically isolated mucoid strain with comprehensive carbapenem resistance mechanisms. *BMC Microbiology*, **2021**, 21, 133 | 4.5 | 3 |
| 43 | Cystic fibrosis. *Lancet, The*, **2021**, 397, 2195-2211 | 40 | 57 |
| 42 | Is it Worth Adding Systemic Antibiotics to Inhalational Tobramycin Therapy to Treat Pseudomonas Infections in Cystic Fibrosis?. *Cureus*, **2021**, 13, e17326 | 1.2 | |
| 41 | Development of potent antipseudomonal lactams by means of polycarboxylation of aminopenicillins. *Microbiology and Immunology*, **2021**, 65, 449-461 | 2.7 | |
| 40 | Regulation of Biofilm Exopolysaccharide Production by Cyclic Di-Guanosine Monophosphate. *Frontiers in Microbiology*, **2021**, 12, 730980 | 5.7 | 2 |
| 39 | Phylogenomic and comparative genomic analyses of species of the family : Proposals for the genera gen. nov. and gen. nov., merger of the genus with the genus , and transfer of some misclassified species of the genus into other genera. *International Journal of Systematic and Evolutionary Microbiology*, **2021**, 71, | 2.2 | 4 |

| | | | |
|---|---|---|---|
| 38 | A Rapid and Sensitive Detection Method for Using Visualized Recombinase Polymerase Amplification and Lateral Flow Strip Technology. *Frontiers in Cellular and Infection Microbiology*, **2021**, 11, 698929 | 5.9 | 2 |
| 37 | Management of chronic infection with inhaled levofloxacin in people with cystic fibrosis. *Future Microbiology*, **2021**, 16, 1087-1104 | 2.9 | 3 |
| 36 | Bronchial Infection due to Pseudomonas Aeruginosa in Patients with Cystic Fibrosis Diagnosed in Neonatal Screening. *Archivos De Bronconeumologia*, **2020**, 56, 532-534 | 0.7 | 1 |
| 35 | A structure-function analysis of interspecies antagonism by the 2-heptyl-4-alkyl-quinolone signal molecule from. *Microbiology (United Kingdom)*, **2020**, 166, 169-179 | 2.9 | 3 |
| 34 | Development of an Interdisciplinary Telehealth Care Model in a Pediatric Cystic Fibrosis Center. *Telemedicine Reports*, **2021**, 2, 224-232 | 2 | |
| 33 | RECOMBINANT ANTIGENS OF PSEUDOMONAS AERUGINOSA: EFFECT ON IMMUNE RESPONSE IN MICE. *Zhurnal Mikrobiologii Epidemiologii I Immunobiologii*, **2017**, 52-58 | 0.5 | |
| 32 | Building a better biofilm - formation of in vivo-like biofilm structures by Pseudomonas aeruginosa in a porcine model of cystic fibrosis lung infection. | | 1 |
| 31 | The Evolution of Precision Medicine in Cystic Fibrosis. *Respiratory Medicine*, **2020**, 57-69 | 0.2 | |
| 30 | Chest Radiographic and Chest CT Images of Aspiration Pneumonia: Are the Image Features of Aspiration Pneumonia Different from Those of Non-aspiration CAP or HAP?. *Respiratory Disease Series*, **2020**, 35-47 | 0.2 | 1 |
| 29 | Pseudomonas aeruginosa cytochrome P450 CYP168A1 is a fatty acid hydroxylase that metabolizes arachidonic acid to the vasodilator 19-HETE. | | 1 |
| 28 | The Role of Virulence Factors in Cytoskeletal Dysregulation and Lung Barrier Dysfunction. *Toxins*, **2021**, 13, | 4.9 | 2 |
| 27 | Advances in the development of antimicrobial peptides and proteins for inhaled therapy. *Advanced Drug Delivery Reviews*, **2021**, 180, 114066 | 18.5 | 4 |
| 26 | A panel of diverse clinical isolates for research and development.. *JAC-Antimicrobial Resistance*, **2021**, 3, dlab179 | 2.9 | 0 |
| 25 | Pseudomonas aeruginosa cytochrome P450 CYP168A1 is a fatty acid hydroxylase that metabolizes arachidonic acid to the vasodilator 19-HETE.. *Journal of Biological Chemistry*, **2022**, 101629 | 5.4 | 2 |
| 24 | Die Zinkhom□stase von Pseudomonas aeruginosa als potenzielles Target f□virulenzmindernde Wirkstoffe □Konzept und Screening von Naturstoffen. *Zeitschrift Fur Phytotherapie: Offizielles Organ Der Ges F Phytotherapie E V*, **2022**, 43, 14-20 | 0.1 | |
| 23 | The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis.. *International Journal of Molecular Sciences*, **2022**, 23, | 6.3 | 2 |
| 22 | Identification of an Au(I) N-Heterocyclic Carbene Compound as a Bactericidal Agent Against .. *Frontiers in Chemistry*, **2022**, 10, 895159 | 5 | 2 |
| 21 | Impact of Subinhibitory Concentrations of Metronidazole on Morphology, Motility, Biofilm Formation and Colonization of Clostridioides difficile. *Antibiotics*, **2022**, 11, 624 | 4.9 | |

| | | | |
|---|---|---|---|
| 20 | The effect of Pseudomonas aeruginosa eradication regimens on chronic colonization and clinical outcomes in pediatric patients with cystic fibrosis. *Pediatrics International*, | 1.2 | 0 |
| 19 | Bronchiectasis in patients with antineutrophil cytoplasmic antibody-associated vasculitis: a case control study on clinical features and prognosis. *Expert Review of Respiratory Medicine*, 1-9 | 3.8 | |
| 18 | Probability of Target Attainment of Tobramycin Treatment in Acute and Chronic Pseudomonas aeruginosa Lung Infection Based on Preclinical Population Pharmacokinetic Modeling. *Pharmaceutics*, **2022**, 14, 1237 | 6.4 | |
| 17 | Insulin-Like Growth Factor Binding Protein (IGFBP-6) as a Novel Regulator of Inflammatory Response in Cystic Fibrosis Airway Cells. *Frontiers in Molecular Biosciences*, 9, | 5.6 | 2 |
| 16 | Phenotypic and integrated analysis of a comprehensive Pseudomonas aeruginosa PAO1 library of mutants lacking cyclic-di-GMP-related genes. *Frontiers in Microbiology*, 13, | 5.7 | 0 |
| 15 | Emergence of Small Colony Variants (SCVs) is an adaptive strategy used by Pseudomonas aeruginosa to palliate O2 limitations. | | |
| 14 | How to Manage Pseudomonas aeruginosa Infections. **2022**, 425-445 | | 0 |
| 13 | Pseudomonas aeruginosa reference strains PAO1 and PA14: A genomic, phenotypic, and therapeutic review. 13, | | 0 |
| 12 | Prediction of Potential Drug Targets and Vaccine Candidates Against Antibiotic-Resistant Pseudomonas aeruginosa. **2022**, 28, | | 0 |
| 11 | Host cell responses against the pseudomonal biofilm: A continued tale of host-pathogen interactions. **2023**, 174, 105940 | | 0 |
| 10 | Pseudomonas aeruginosa Represents a Main Cause of Hospital-Acquired Infections (HAI) and Multidrug Resistance (MDR). | | 0 |
| 9 | Diversity and prevalence of type VI secretion system effectors in clinical Pseudomonas aeruginosa isolates. 13, | | 0 |
| 8 | A Case Study on Using Reddit Comments as a Source of Information on Patients Experiences and Concerns: Text Analyses on r/CysticFibrosis (Preprint). | | 0 |
| 7 | The challenge of pulmonary Pseudomonas aeruginosa infection: How to bridge research and clinical pathology. **2023**, 591-608 | | 0 |
| 6 | Impact of mucus and biofilm on antimicrobial photodynamic therapy: Evaluation using Ruthenium(II) complexes. **2023**, 5, 100113 | | 0 |
| 5 | Antibiotikagabe: Wie kurz ist lang genug?. **2023**, 15, 16-17 | | 0 |
| 4 | Emergence of Small Colony Variants Is an Adaptive Strategy Used by Pseudomonas aeruginosa to Mitigate the Effects of Redox Imbalance. **2023**, 8, | | 0 |
| 3 | IgA-producing B cells in lung homeostasis and disease. 14, | | 0 |

| | | |
|---|---|---|
| 2 | Current and Emerging Inhaled Antibiotics for Chronic Pulmonary Pseudomonas aeruginosa and Staphylococcus aureus Infections in Cystic Fibrosis. **2023**, 12, 484 | 0 |
| 1 | Disruptions in the Cystic Fibrosis Community's Experiences and Concerns During the COVID-19 Pandemic: Topic Modeling and Time Series Analysis of Reddit Comments. 25, e45249 | 0 |